

**Impact of diabetes susceptibility loci on progression from pre-diabetes to diabetes in at-risk individuals of the DPT1 trial**

*Vincent Butty, MD, Christopher Campbell, BS, Diane Mathis, PhD, Christophe Benoist, MD, PhD,*

*and the Diabetes Prevention Trial-Type 1 Study Group.*

Section on Immunology and Immunogenetics, Joslin Diabetes Center, Department of Medicine,  
Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215

Address correspondence to:

Diane Mathis and Christophe Benoist

Section on Immunology and Immunogenetics

Joslin Diabetes Center

One Joslin Place, Boston, MA 02214

email: [cbdm@joslin.harvard.edu](mailto:cbdm@joslin.harvard.edu)

Received 11 December 2007 and accepted 5 June 2008.

Additional information for this article can be found in an online appendix at

**<http://diabetes.diabetesjournals.org>**

This is an uncopyedited electronic version of an article accepted for publication in *Diabetes*. The American Diabetes Association, publisher of *Diabetes*, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of *Diabetes* in print and online at <http://diabetes.diabetesjournals.org>.

*Objective:* The unfolding of type-1 diabetes (T1D) involves a number of steps: defective immunological tolerance, priming of anti-islet autoimmunity, destruction of insulin-producing  $\beta$ -cells. A number of genetic loci contribute to susceptibility to T1D, but it is unclear which stages of the disease are influenced by the different loci. Here, we analyzed the frequency of T1D-risk alleles among individuals from the DPT1 clinical trial, which tested a preventive effect of insulin in at-risk relatives of diabetic individuals, all of which presented with autoimmune manifestations, but only 1/3 of which eventually progressed to diabetes.

*Design:* 708 individuals randomized into DPT1 were genotyped for 37 SNPs in diabetes susceptibility loci.

*Results:* Susceptibility alleles at loci expected to influence immunoregulation (*PTPN22*, *CTLA4*, *IL2RA*) did not differ between progressor and non-progressors, but were elevated in both groups relative to general population frequencies, as was the *INS* promoter variant. In contrast, *HLA DQB1\*0302* and *DQB1\*0301* differed significantly in progressors vs. non-progressors (*DQB1\*0302*: 42.6% vs. 34.7,  $p=0.0047$ ; *DQB1\*0301*: 8.6% vs. 14.3%,  $p=0.0026$ ). Multivariate analysis of the factors contributing to progression demonstrated that initial titers of anti-insulin autoantibodies (IAA) could account for some ( $p=0.0016$ ), but not all of this effect on progression ( $p=0.00038$  for the independent effect of the number of *DQB1\*0302* alleles). The *INS-23* genotype was most strongly associated with anti-insulin autoantibodies (median IAA levels in TT individuals 60 nU/ml, AT 121 and AA 192,  $p=0.000037$ ), and only suggestively to the outcome of oral insulin administration.

*Conclusion:* With the exception of *HLA*, most susceptibility loci tested condition the risk of autoimmunity rather than the risk of failed immunoregulation that results in islet destruction. Future clinical trials might consider genotyping *INS-23* in addition to HLA alleles as disease/treatment response modifier.

**T**ype-1 diabetes (T1D) is an autoimmune disease characterized by destruction of the insulin-producing  $\beta$ -cells in the pancreatic islets. Although its etiology is not yet understood, strong genetic and environmental components appear to modulate individual disease susceptibility, both in patients and in animal models (1). The major histocompatibility complex (MHC) is the primary genetic determinant of susceptibility to T1D in both in human patients and the NOD mouse model (2). In addition, numerous genetic studies in humans and mice have led to the description of additional susceptibility loci (*IDDM* and *Idd*, respectively), for which the causative genes have yet to be fully defined in most cases. The best evidence exists for polymorphisms in the promoter region of the Insulin gene, which may impact on ectopic expression of this locus in the thymus, and thereby modulate immunological tolerance through clonal deletion of autoreactive thymocytes (3;4). More recently, polymorphisms in *PTPN22* and *CTLA4*, two genes key in the fine-tuning of immune responses, have been associated with T1D (5;6). Several other susceptibility loci have recently been described in genome-wide association studies performed in large cohorts (7-9). Although their identity, biological significance, and functional impact remain to be elucidated, some of these susceptibility loci appear to be shared across several autoimmune diseases, suggesting the existence of common regulatory steps whose dysfunction may lead to autoimmunity (e.g. *PTPN22* is associated with Graves' thyroiditis, T1D and Rheumatoid Arthritis, among others).

This complex genetic determinism matches the multiple steps and checkpoints involved in the pathogenesis of T1D. A likely first step is the defective induction of tolerance to self-antigens in immature thymocytes, as demonstrated in the NOD

mouse model (10-12), and suggested by the impact of *INS* promoter polymorphisms in human patients (3;4). A second phase involves activation of autoreactive cells in the periphery, followed by lymphocytic infiltration of pancreatic islets, and the production of autoantibodies. Although clinically silent, metabolic studies can demonstrate impaired insulin secretion, or altered first phase insulin release after intravenous glucose challenge, and a flattening of the physiological increase in C-peptide with age (13;14).

This prodromic phase can persist for long periods of time in both mice and humans; indeed, many such pre-diabetic individuals may never progress to overt diabetes. In the final disease stage, the insulitic infiltration results in massive destruction/functional incapacitation of  $\beta$ -cells, culminating in loss of glycemic control. In animal models, several factors appear to impact on these checkpoints, in particular the timing of self-antigen availability for presentation in the pancreatic lymph nodes, the functionality of regulatory T cells, and infectious or related environmental challenges (reviewed in (15;16)). In such models, loci that affect the breakdown of immunological tolerance could be distinguished from others that control later steps of immunoregulation or the aggressivity of the attack on the islets (10;11;17;18). Whether such checkpoints occur in humans is unknown, although the long prodromic phase that precedes onset in at-risk individuals suggests the existence of similar immunological and genetic steps.

The notion of checkpoints controlled by different mediators raised the hope that pre-diabetic individuals might be prevented from developing full-blown diabetes by re-establishing tolerance and halting the autoimmune process, allowing islet regeneration to take place naturally. Diabetes Prevention Trial-Type 1 (DPT1) was set-up

with the specific goal of identifying anti-islet cytoplasmic antibody-positive (ICA+) first-degree relatives of T1D patients at risk for developing T1D themselves, and treating them with daily low-dose subcutaneous and yearly 4-day iv insulin (parenteral insulin trial) or oral insulin to prevent loss of glycemic control (19). This study was based on results from NOD mice (although the protocol used was very different) as well as small pilot studies in human patients (20-23). Neither the parenteral nor the oral insulin treatments resulted in significant modification of diabetes incidence, although post-hoc analysis suggested a slight treatment effect in the subgroup with the highest IAA titers at baseline (19;24). In the context of this trial, a large amount of high-quality longitudinal data was collected, representing a unique opportunity to study the genetic factors underlying progression to overt diabetes in antibody-positive individuals.

The primary goal of the present study was to gauge the contribution of T1D-susceptibility loci to the transition to full-blown diabetes, and thus to elucidate which stage of the disease is impinged upon by such loci. We genotyped SNPs in a number of known or putative T1D-susceptibility loci, and also re-considered the HLA data (19) from the particular angle of distinguishing progressor from non-progressor individuals. Beyond the implications for our understanding of the pathogenic processes in T1D, this distinction could have direct clinical consequences, by allowing a more accurate definition of the risk of progression in pre-diabetic individuals. Improved prediction would facilitate the design of prevention trials, and/or define individuals at particularly high risk for whom more aggressive therapeutic regimens might be warranted.

## RESEARCH DESIGN AND METHODS

**Identification and randomization of subjects.** This study is based on the data published in (19;24). Briefly, relatives of T1D patients were screened for islet cell autoantibodies (ICA). In case of a positive result, insulin autoantibodies (IAA), beta cell function, glucose tolerance status, and HLA genotype was determined. ICA and IAA positive individuals with preserved islet function without HLA DQB1\*0602 alleles were deemed to be at intermediate risk and eligible for randomization to oral insulin or placebo, while similar individuals with an abnormal response to intravenous glucose challenge (IVGTT) were considered high-risk, and were randomized in the parenteral insulin trial (intravenous and subcutaneous).

In this study, all demographic, clinical, biochemical and HLA data were obtained from the original study database after deidentification of the subjects (the April 30<sup>th</sup>, 2003 release of the clinical and phenotypic data, with antibody data from the November 1<sup>st</sup> 2004 release). Allele frequencies of parents of T1D patients were retrieved from the T1DGC study (25).

**Single Nucleotide Polymorphism (SNP) typing.** T1D-susceptibility SNPs were chosen based on the available literature ((5;7-9;26-32), and our unpublished data). Starting from amplified genomic DNA provided by the NIDDK Central Repository, SNPs were genotyped with fluorogenic allele-discrimination chemistry, as described (11). Primers and probes are described in Supplementary Table 1.

**Statistical analyses.** Categorical variables were analyzed by the chi square test or Fisher's exact test if the counts were less than 5 in one of the cells. Survival differences among groups were assessed by the log-rank test. Cox proportional hazard modeling was applied to multivariate analysis of survival parameters. Kaplan-Meier survival probability function was used to plot risk of diabetes onset among subgroups. Impact of

SNP genotype classes on IAA levels was assessed by linear regression on log-transformed initial IAA values. Data were analyzed with the survival package in the R statistical environment (cran.r-project.org). Since most showed no significance, p-values reported here are not corrected for multiple sampling; those tests showing potential significance were re-considered with a simple Bonferroni correction, based on the number of SNPs or alleles tested (for HLA alleles, we only corrected for frequent alleles or haplotypes, ignoring those present in <10 individuals). DPT1 parental HLA allele frequencies were estimated based on published transmission disequilibrium of HLA alleles to T1D probands (33-35), according to the following formula:  $\text{ProAF} = \frac{\text{ParAF}^2}{\text{ParAF} + (\text{ParAF}) * (1 - \text{ParAF}) * (\% \text{Transmission to probands} / 50\%)}$ , where ProAF and ParAF are the proband and parental allele frequencies, respectively. Hazard ratios for *INS-23* genotype subsets were computed by Cox proportional modeling. Subgroups of individuals showing maximal treatment efficacy were identified by computing survival differences across individual subsets ranked according to the distribution of log-transformed initial IAA quantiles.

**Haplotype reconstruction.** *CTLA4* haplotypes were reconstructed using PHASE2.1 (36) and pooling data from progressors and non-progressors. The algorithm was run according to the authors' recommended procedure, and the output was checked for consistency with different seeds for random numbers generation.

## RESULTS

The goal of this study was to test whether any of the loci so far associated with susceptibility to T1D might condition progression from the pre-diabetic to the diabetic state, as opposed to influencing the autoimmune deviation that results in pre-

diabetes. To that end, DNA samples and full clinical information were obtained from individuals randomized into the DPT1 study. As described (19), more than 100,000 relatives of T1D patients were screened for autoantibodies (ICA test), identifying 3483 positive individuals (Suppl. Figure 1). To be further considered in the study, ICA+ individuals had to lack protective HLA-DQA1\*0102/ DQB1\*0602 alleles. Individuals with an abnormal IVGTT or insulin-release assay were eligible for randomization into the high risk/parenteral insulin group, while subjects with high IAA titers and preserved IVGTT/OGTT were eligible for the medium-risk oral insulin trial. 418 high-risk and 388 medium-risk individuals were identified, which were randomized between the arms of the study, and for which excellent follow-up was performed during the years of the DPT1 trial. Of these, 258 individuals progressed to clinical diabetes during the follow-up period. The age distribution (Supplementary Fig. 2) showed the existence of one group of individuals (n=638), whose mean age at screening was 3461 days (9.5 y, range 372 to 9628 d), and a second group (n=70) with a mean age at randomization of 13597 days (37.3 y, range 10075 to 16340 d), leading to a bimodal distribution (goodness-of-fit to normality by Kolmogorov-Smirnov  $p=10^{-70}$ ). More importantly, the incidence of progression for the individuals screened after 10,000 days of age was distinctly lower (14% vs. 39%). Thus, we did not include this subgroup to avoid diluting true genetic effects. The remaining group of 638 individuals included in our studies encompassed 485 children screened at age < 4500 days (12.3 y, 76%). In the 258 individuals who progressed to T1D, the median time from screening to diagnosis of T1D was 3.7 years (5%-95% 1.2 to 7 y).

**Non-HLA diabetes susceptibility loci and progression.** We first addressed the impact of

convincingly associated, non-HLA T1D-susceptibility polymorphisms on diabetes progressor/non-progressor outcome. These included the *INS* -23 promoter polymorphism, the *PTPN22* R620W coding-region change, and several 3'UT and intronic polymorphisms in the *CTLA4* costimulatory gene (the CT60 marker and other SNPs, since the causal polymorphism in the costimulatory region remains in question). We also genotyped a number of variants for which the evidence is more recent or less substantially replicated, including some discovered in the context of genome-wide association studies (acknowledging that the low effect of these recently-described variants would likely make the present cohort underpowered) (5;7-9;26-32;37).

These SNPs were genotyped using fluorogenic PCR with a success rate of 98.3% (96% of individuals with 93% or more genotyping success, and 100% concordance rate upon repeated genotyping of a handful of markers in all individuals). Because some of these markers have shown strong population differentiation (e.g. the absence of *PTPN22* R620W T in Asian populations), we restricted our analyses to Caucasian individuals screened at <10000 d (n=575), which constitute the majority of subjects recruited into DPT1. As depicted in Table 1, no polymorphism showed a significant difference between DPT1 progressors (P) and non-progressors (NP), with the exception of a SNP in Lymphotoxin- $\alpha$  (*LTA*), likely reflecting HLA haplotypes (see below). For a number of SNPs, the allele frequencies in both the P and NP groups matched well those usually reported in T1D patients. For example, the *PTPN22* R620W T variant is present in ~8% of non-affected US Caucasian populations, 15-20% of T1D patients, 15 and 17 % of NP and P DPT1 individuals, respectively. A similar distribution was found for the *INS* -23 A variant (unaffected: 24-32%, T1D: 12-18%, NP: 20%, P: 17%), and

for *CTLA4* CT60 G (unaffected: 52%, T1D: 57-63%, NP 60% and P: 61%).

Recently described polymorphisms in the *TCF7L2*, *HHEX* and *SLC30A8* loci that predispose to T2D (38) were also tested, since islet dysfunction could precipitate diabetes; no difference in these markers was observed between progressors and non-progressors (Table 1).

Skewed allele frequencies were observed across most *CTLA4* SNPs, in addition to CT60, and in the neighboring *CD28* and *ICOS* genes. Building on a recent population genetics study of the *CD28* costimulatory locus (28), we computationally reconstructed haplotypes across *CTLA4* in P and NP individuals. As depicted in Fig. 1, the *CTLA4*.h1 haplotype carries all high-risk *CTLA4* alleles (CT60 G, +49 G, JO31 G), while *CTLA4*.h2 regroups most low-risk alleles, and is part of a very homogeneous extended haplotype that spans the whole costimulatory locus from *CD28* to the *ICOS* promoter region (28). Among DPT1 individuals, *CTLA4*.h1 haplotype was enriched both in P and NP, leading to an inversion of the h1/h2 frequency ratio relative to the general population (Fig. 1B). *CTLA4*.h2 appeared to be more underrepresented in DPT1 subjects compared with a US Caucasian control cohort (DCGS) than did any of its individual allelic SNP components (Fig. 1B). Similarly, a recent study of the costimulatory locus in patients with celiac disease showed that extended haplotypes in the region demonstrated stronger association with disease susceptibility than did individual SNPs (39).

Thus, these results suggest that the strongest non-HLA susceptibility alleles impact T1D pathogenesis at an early stage, conditioning whether tolerance is broken and autoimmunity sets in, but have less or no influence on the course of disease and the probability that this autoimmunity will lead to terminal  $\beta$ -cell destruction.

**HLA.** Class II genes at the HLA locus represents the strongest genetic determinant of T1D susceptibility (1;2). We chose to analyze the distribution of HLA alleles and their combinations in a stepwise fashion, to avoid dilution of effect by multiple genotypic combinations. Table 2 represents the distribution of HLA-DQB alleles among 638 individuals randomized into the DPT1 trial (association with single DQA alleles showed no strong signal by themselves, or only that expected from their linkage disequilibrium (LD) to DQB alleles – see below). Since DPT1 was based on first-degree relatives of T1D patients, allele frequencies in such families were bound to be enriched in susceptibility alleles, thus precluding the use of frequency data in healthy controls as a comparator. Thus, we inferred allele frequencies in the parental population of DPT1 individuals based on the HLA allele frequencies of progressors (i.e. T1D patients) and the known transmission disequilibrium biases of alleles to T1D probands (33-35). As an additional comparison, parental data from the T1D genetic consortium (T1DGC) were retrieved (25). In comparison with these frequencies, which represent a null-hypothesis baseline for no association, a strong enrichment for DQB1\*0201 and allele was observed, both in P and NP individuals, with a weaker trend in DQB\*0302. The frequency of \*0201 alleles was the same in both groups, but DQB1\*0302 was enriched in P relative to NP (P 42.6% vs. NP 34.7%, OR 1.39,  $p = 0.0047$ , or  $p \sim 0.042$  after correcting for multiple sampling). The reverse held true for DQB1\*0301, as this protective allele was significantly less frequent in P than in NP (P 8.6% vs. NP 14.3%, OR 0.57,  $p = 0.0026$ , corr  $p \sim 0.023$ ). None of the other alleles appeared differentially represented in P vs. NP, with frequencies comparable with that of the parental population. These results suggest that T1D-susceptibility loci in the MHC can impact several levels of the disease process.

Not only can they increase the probability of autoimmunity, but some haplotypes also appear to condition the chance of progression from pre-diabetes to diabetes.

We also performed log-rank survival analyses to compare the kinetics of progression to T1D of individuals carrying different HLA alleles. As seen in Fig.2A, the time-to-T1D-onset was markedly influenced by the presence of \*0302 alleles, in a dose-dependent manner: median onset with no \*0302 allele was 6.12 years, a single \*0302 allele was 4.71 years, and with two alleles was 3.65 years,  $p = 2 \cdot 10^{-4}$ . Conversely, \*0301 alleles delayed the progression to overt T1D, also in a dose-dependent manner. These findings held true when only high-risk individuals were considered (Fig. 2B). Since it is known that T1D in very young individuals has a specific genetic architecture (31), we asked whether DQB alleles impacted differently on T1D incidence based on the age of the individual, splitting at 5000d which roughly corresponds to the pubertal period (Fig. 2C). Individuals homozygous for DQB\*0302 showed an increased incidence of T1D and faster kinetics of progression irrespective of age, while the incidence of T1D significantly dropped after 5000d in subjects lacking \*0302. On the other hand, the protective effect of DQB\*0301 was mostly visible in the >5000d group.

We then asked whether combinations of DQ $\beta$  alleles might differentially impact on progression. Table 2B assesses the representation of the second DQB1 allele among P and NP individuals already positive for DQB1\*0302, \*0301, or \*0201. For 0302-positive individuals, none of the additional alleles had meaningful impact in either direction (save for the enhancement of progression in DQB1\*0302 homozygotes, consistent with Fig. 2). On the other hand, the \*0301/\*0201 combination was significantly underrepresented in progressors, whether compared to all \*0301-positive or to all

\*0201-positive individuals ( $p \sim 0.02$  and  $0.0016$ , respectively), suggesting a strong epistatic interaction between these two alleles (or with the other loci linked to these variants within the MHC). In contrast, the \*0301 allele had no impact in \*0302-positive individuals.

Since non-random pairing exists between DQA\* and DQB\* alleles in strong LD, we compared the representation of specific DQA alleles in individuals bearing DQB1\*0302, \*0301 and \*0201 (Supplementary tables S2-4). In individuals heterozygous for the DQB allele of interest, we used direct DQA allele counting instead of reconstructing two-loci haplotypes in double heterozygous (which can only be estimated, since their true gametic phase is unknown), which provided sensitivity for DQA-DQB *trans*-complementation effects. For DQB1\*0302 individuals, the diversity in DQA allele representation was essentially restricted to heterozygous individuals, given the complete LD between DQA\*0301 and DQB1\*0302, and no significant modulation of the progression was observed. On the other hand, DQB1\*0201's impact was somewhat modified by the presence of certain DQA alleles: DQA\*0201 was protective, DQA\*0501 promoted progression but only in DQB\*0201 homozygotes. No significant impact of DQA was observed in DQB\*0301-positive individuals, although expected trends towards an enrichment of DQA\*0301 in progressors and DQA\*0501 in non-progressors were seen.

**Treatment effects.** Insulin had no significant effect overall in DPT1, except for individuals with high anti-insulin autoantibodies treated with oral insulin (19;24), but we asked whether stratification by genotype might show a different outcome. No difference was found upon stratification in DQB1\*0302 (Fig. 3) or \*0301 (not shown) subgroups. For the *INS*-23 polymorphism, a significantly enhanced effect of the oral treatment was seen in individuals heterozygous for the

susceptibility allele; this result should be interpreted with caution, however, as it was not reproduced in homozygotes, and the nominal degree of significance ( $p=0.028$ ) would not resist proper correction for multiple sampling. On the other hand, it is interesting that the group of *INS*-23A heterozygotes is that which shows high IAA titers (see below), and thus likely overlaps with the high-IAA subgroup which showed some treatment effect in post-hoc analyses (24). Comparative survival analysis showed very similar hazards ratio for treatment effect among high-IAA ( $>75^{\text{th}}$  percentile) and among *INS*-23A heterozygotes ( $0.41$  (95%CI  $0.2-0.85$ ) and  $0.36$  ( $0.15-0.87$ ), respectively).

**T1D susceptibility loci and initial autoantibody levels.** We then used linear regression to ask whether any of the genetic markers investigated showed an association with the level of autoantibodies in at-risk individuals. Antibody titers at screening were used for that purpose, instead of summing the counts of positive antibodies which might mask specific effects of a given polymorphism on distinct antibody reactivities (acknowledging that fluctuations in the titers could be observed over the course of a few months, and that the elapsed time since seroconversion was unknown).

Only the *INS*, *ICOS* and HLA variants showed an association with IAA titers (Tab. 3). Genotypes at *INS* -23 appeared to be the most strongly associated with differences in baseline IAA levels ( $p=3.7 \cdot 10^{-5}$ , or  $\sim 1.5 \cdot 10^{-3}$  after correction for multiple sampling), which is consistent with previous reports (40-42). The effect was dominant: individuals heterozygous or homozygous for the high-risk allele both demonstrated a 2.4-fold increase in median IAA levels at baseline. A weak association was observed with DQB1\*0302; of note, most of the *INS*-23 association with IAA titers was found in DQB\*0302 negative individuals. The DQB1\*0201 susceptibility allele was negatively associated with IAA

levels. These results suggest complex mechanistic interactions of HLA susceptibility haplotypes, with a different effect on IAA for the \*0302 and \*0201 susceptibility alleles.

Redondo et al observed the same association between DQB1\*0302 and anti-insulin titers, but came to the conclusion that progression to T1D in the DPT1 cohort was only indirectly correlated with HLA-DQ status, and that the risk of progression to overt diabetes was actually correlated with the number of autoantibodies present at randomization, HLA-DQ status being only a modulator of this number (43) (similarly counting the number of positive antibodies in our restricted subset also showed that HLA impacted the progression to T1D mostly in individuals with 0-2 autoantibodies; not shown). Since our analysis, which was restricted to the individuals actually enrolled in the trial, argued for more complex HLA effects in relation to IAA levels (and not mere positivity) and T1D progression, we asked whether these parameters were truly independent by building uni- and multivariate Cox proportional hazards models including DQB1\*0302, \*0301 and baseline IAA levels. As shown in Fig. 4A, both baseline IAA and the number of DQB1\*0302 alleles were independently associated with faster progression towards T1D. This effect of HLA alleles, independent of IAA, is graphically illustrated by the multivariate Cox analysis of the predicted time-to-progression for individuals with different numbers of \*0302 alleles, with IAA levels conditioned on their average value (Fig. 4B).

For anti-glutamic acid decarboxylase (GAD) 65 antibodies, only a weak association with polymorphisms in *CD25* (Supplementary Table 5) was found, compatible with an additive effect (e.g. median titers 0.185, 0.215 and 0.467 for 0, 1 and 2 rs706778 A alleles; p=N.S. when corrected for multiple sampling).

## DISCUSSION

The goal of this study was to identify amongst known or suspected T1D-susceptibility loci those impinging on conversion from the pre-diabetes to the diabetic state. A clear association was observed with some, but interestingly not all, HLA class II alleles, an influence that went beyond their relation to initial IAA levels. On the other hand, none of the extra-HLA polymorphisms differed significantly in frequency between progressors vs. non-progressors, a number of them (notably *INS-23*, *PTNP22 R620W* and several *CTLA4* markers) showing the typical elevated frequencies of susceptible alleles in DPT1 individuals, irrespective of eventual progression to overt diabetes. These results, obtained in individuals <10000 days old at screening, still held true when considering the whole cohort irrespective of age (not shown).

The implication of these results is that most non-HLA T1D-susceptibility loci described so far affect the initial breakdown of immunological tolerance and the initiation of autoimmunity, rather than the later failures of immunoregulation that lead to terminal islet destruction. It is quite plausible that the *INS-23A* polymorphism would affect tolerance: together with the length polymorphism of the VNTR element further upstream in the *INS* promoter region, with which it is in tight LD, it is thought to lower thymic expression of insulin and lead to less effective induction of T cell tolerance to insulin (3;4). The significant association between the *INS* susceptibility alleles and higher titers of anti-insulin antibodies, which confirm prior observations associating *INS-23* to IAA incidence in Scandinavian cohorts (40-42), is also consistent with this notion. *PTPN22* encodes a regulatory phosphatase that modulates TCR signaling, and one might hypothesize that the variant modifies signaling in immature thymocytes and hence tolerance induction, or the activation of

autoreactive T cells in the periphery. *CTLA4* and *CD25*, because of their involvement in regulatory T cells, might have been thought *a priori* to impact on diabetes progression, but this proved not to be the case. Here also, one might invoke an effect on T cell activation at the initiation of autoimmune T cell infiltration. **HLA.** Only HLA-DQ alleles showed a noticeable effect on T1D progression in DPT1 individuals, partially in correlation with enhancement of IAA levels, but also with effects independent of IAA titers. The data confirm an earlier report of an association of IAA and IA-2 positivity with the presence of DQB\*0302 in Scandinavian T1D patients (40). Redondo et al. have also reported an analysis of HLA haplotypes and genotypes in relation to autoantibodies and disease progression in the DPT1 cohort (43), albeit with a different strategy that encompassed all ICA-positive individuals genotyped for HLA (n=2046), potentially diluting a genetic effects on progression in high-risk individuals by the inclusion of many low-risk individuals, and focused on compound genotypes rather than individual alleles. These authors also observed the relationship between progression and DQB1\*0302 and \*0301, and found that 57% of DQB\*0302-homozygous individuals were positive for 2 or more antibodies, compared to only 30% of DQA\*0501/DQB\*0201 homozygous ( $p=3 \times 10^{-9}$ ), yet both genotypes had roughly the same 5-year T1D risk when considering their larger cohort (36% vs. 34%). Redondo et al. concluded that a relationship between DQB genotypes and number of different autoantibodies at screening could account for these effects on progression (HLA being irrelevant in individuals with 2 or more autoantibodies in their data). The quantitative survival analysis performed here, based on measured titers rather than on positive/negative calls, indicates that the picture is more complex, demonstrating the

limitations of imposing cut-offs when dissecting a quantitative trait.

Indeed, the two main susceptibility alleles (DQB1\*0302 and \*0201) appear to have different impacts in several respects: \*0302 has a direct effect on the risk of progression, while \*0201 does not; \*0302 has a moderate association to IAA titers, \*0201 does not; \*0201 is associated with higher GAD65 titers (40), \*0302 is not; the impact of \*0201 varies with the DQA chain with which it is paired (in *cis* or *trans*), \*0302 does not; \*0201 has a strong epistatic interaction with \*0301, resulting in protection of \*0201/\*0301 heterozygotes, while \*0302 does not. These observations are consistent with the notion that \*0302 and \*0201 provide mechanistically different contributions to disease pathogenesis beyond a mere modulation of antibody numbers (44-47).

How could HLA be involved at different stages of the autoimmune pathogenesis? Early effects on tolerance, for instance by allowing the emergence of a T cell repertoire with reactivity against islet peptides (insulin?), might be expected from their role in selecting T cells and presenting self-antigens. In the NOD mouse, the H2<sup>g7</sup> MHC alleles associated to T1D are sufficient to select an autoreactive repertoire (48). More puzzling is the additional contribution of DQB1\*0302 to further progression. The enrichment in heterozygous \*0302 individuals among progressors might mirror a multistage process wherein the initial trigger is amplified through the presentation of later-stage “epitope-spreading” antigens, at which \*0302 would be particularly efficient. Alternatively, HLA class II alleles might mediate sensitivity to environmental insults (e.g. infections or food-borne antigens) after the establishment of a “respectful” insulinitis, perhaps tipping the balance towards immune activation and full-blown islet destruction. Finally, it is plausible that the negative epistasis between DQB1\*0201 and DQB1\*0301 reflects the

ability of MHC class II molecules to form trans-encoded  $\alpha\beta$  dimers. As usual for loci in the HLA region, this discussion must be cautioned by the strong and complex LD structure in the region. While these effects may be ascribed to the DQB alleles themselves, it is also possible that some of them arise from loci in LD with the DQB alleles, for instance class I genes (49).

**Pharmacogenetics?** Can one, from this analysis, draw conclusions that would guide the design of other prevention studies, attempting to improve the power of the trials by using genetic data to refine the selection and better define groups of at-risk individuals? Future trials aimed at evaluating prophylactic interventions might require more stringent selection criteria against low-risk or protective HLA genotypes such as DQB\*0301 (DQB\*0602 was already an exclusion criteria in DPT1), which might lead to artefactual treatment efficacy results if unbalanced among the study arms (50). The selection of DQB1\*0302 individuals would improve the power (power calculations show that a ~20% reduction in total group size could be achieved by selecting only \*0302-positive individuals), but such a selection would clearly leave out an important fraction of T1D patients.

While there was no significant effect of oral insulin administration over the entire

pool of DPT1 medium-risk subjects, post-hoc analysis did reveal a slight treatment effect in the subgroup with the highest initial IAA titers (19;24). We found that stratification by *INS-23* genotype also uncovered a significant effect of oral insulin treatment in heterozygotes (with the limitations on validity of any such post-hoc analysis). Given the association between *INS-23* genotype and IAA levels, one might expect that the two observations are linked, and subgroup analysis indeed confirmed this to be true. In other trials of oral insulin, it may be of interest to select candidates on the basis of *INS-23* as well as IAA titers, to test the significance and reproducibility of these observations.

#### ACKNOWLEDGEMENTS

We thank Drs. C. Greenbaum and the DPT1 Publications Committee for inspiring discussions, the NIDDK Central DNA Repository for making samples available, W. Besse for help with genotyping, and all the DPT-1 participants. This work was funded by the National Institutes of Health grant P01-AI056299, the William T. Young Chairs in Diabetes Research, and the Joslin Diabetes and Endocrinology Research Center funded cores. The DPT-1 was supported through cooperative agreements by the NIDDK, NIAID, NHCHHD, ADA and JDRF.

## REFERENCE

1. Eisenbarth,GS: Update in type 1 diabetes. *J Clin Endocrinol Metab* 92:2403-2407, 2007
2. Maier,LM, Wicker,LS: Genetic susceptibility to type 1 diabetes. *Curr Opin Immunol* 17:601-608, 2005
3. Vafiadis,P, Bennett,ST, Todd,JA, Nadeau,J, Grabs,R, Goodyer,CG, Wickramasinghe,S, Colle,E, Polychronakos,C: Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. *Nat.Genet.* 15:289-292, 1997
4. Pugliese,A, Zeller,M, Fernandez,A, Jr., Zalcberg,LJ, Bartlett,RJ, Ricordi,C, Pietropaolo,M, Eisenbarth,GS, Bennett,ST, Patel,DD: The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. *Nat.Genet.* 15:293-297, 1997
5. Bottini,N, Musumeci,L, Alonso,A, Rahmouni,S, Nika,K, Rostamkhani,M, MacMurray,J, Meloni,GF, Lucarelli,P, Pellicchia,M, Eisenbarth,GS, Comings,D, Mustelin,T: A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. *Nat.Genet.* 36:337-338, 2004
6. Ueda,H, Howson,JMM, Esposito,L, Heward,J, Snook,H, Chamberlain,G, Rainbow,DB, Hunter,KMD, Smith,AN, Di Genova,G, Herr,MH, Dahlman,I, Payne,F, Smyth,D, Lowe,C, Twells,RCJ, Howlett,S, Healy,B, Nutland,S, Rance,HE, Everett,V, Smink,LJ, Lam,AC, Cordell,HJ, Walker,NM, Bordin,C, Hulme,J, Motzo,C, Cucca,F, Hess,JF, Metzker,ML, Rogers,J, Gregory,S, Allahabadia,A, Nithyananthan,R, Tuomilehto-Wolf,E, Tuomilehto,J, Bingley,P, Gillespie,KM, Undlen,DE, Renningen,KS, Guja,C, Ionescu-Tirgoviste,c, Savage,DA, Maxwell,AP, Carson,DJ, Patterson,CC, Franklyn,JA, Clayton,DG, Peterson,LB, Wicker,LS, Todd,JA, Gough,SCL: Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. *Nature* 423:506-511, 2003
7. The Wellcome Trust Case Control Consortium: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature* 447:661, 2007
8. Todd,JA, Walker,NM, Cooper,JD, Smyth,DJ, Downes,K, Plagnol,V, Bailey,R, Nejentsev,S, Field,SF, Payne,F, Lowe,CE, Szeszko,JS, Hafler,JP, Zeitels,L, Yang,JH, Vella,A, Nutland,S, Stevens,HE, Schuilenburg,H, Coleman,G, Maisuria,M, Meadows,W, Smink,LJ, Healy,B, Burren,OS, Lam,AA, Ovington,NR, Allen,J, Adlem,E, Leung,HT, Wallace,C, Howson,JM, Guja,C, Ionescu-Tirgoviste,c, Simmonds,MJ, Heward,JM, Gough,SC, Dunger,DB, Wicker,LS, Clayton,DG: Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. *Nat.Genet.* 39:857-864, 2007
9. Hakonarson,H, Grant,SF, Bradfield,JP, Marchand,L, Kim,CE, Glessner,JT, Grabs,R, Casalunovo,T, Taback,SP, Frackelton,EC, Lawson,ML, Robinson,LJ, Skraban,R, Lu,Y, Chiavacci,RM, Stanley,CA, Kirsch,SE, Rappaport,EF, Orange,JS, Monos,DS, Devoto,M, Qu,HQ, Polychronakos,C: A genome-wide association study identifies KIAA0350 as a type 1 diabetes gene. *Nature.* 448:591-594, 2007
10. Kishimoto,H, Sprent,J: A defect in central tolerance in NOD mice. *Nat.Immunol.* 2:1025-1031, 2001
11. Zucchelli,S, Holler,P, Yamagata,T, Roy,M, Benoist,C, Mathis,D: Defective central tolerance induction in NOD mice: genomics and genetics. *Immunity* 22:385-396, 2005
12. Liston,A, Lesage,S, Gray,DH, O'Reilly,LA, Strasser,A, Fahrner,AM, Boyd,RL, Wilson,J, Baxter,AG, Gallo,EM, Crabtree,GR, Peng,K, Wilson,SR, Goodnow,CC: Generalized

- resistance to thymic deletion in the NOD mouse; a polygenic trait characterized by defective induction of Bim. *Immunity* 21:817-830, 2004
13. Steele,C, Hagopian,WA, Gitelman,S, Masharani,U, Cavaghan,M, Rother,KI, Donaldson,D, Harlan,DM, Bluestone,J, Herold,KC: Insulin secretion in type 1 diabetes. *Diabetes* 53:426-433, 2004
  14. Sosenko,JM, Palmer,JP, Greenbaum,CJ, Mahon,J, Cowie,C, Krischer,JP, Chase,HP, White,NH, Buckingham,B, Herold,KC, Cuthbertson,D, Skyler,JS: Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. *Diabetes Care* 29:643-649, 2006
  15. Anderson,MS, Bluestone,JA: The NOD Mouse: A Model of Immune Dysregulation. *Annu Rev.Immunol* 23:447-485, 2005
  16. Tang,Q, Bluestone,JA: Regulatory T-cell physiology and application to treat autoimmunity. *Immunol Rev.* 212:217-237, 2006
  17. Gonzalez,A, Katz,JD, Mattei,MG, Kikutani,H, Benoist,C, Mathis,D: Genetic control of diabetes progression. *Immunity* 7:873-883, 1997
  18. Yamanouchi,J, Rainbow,D, Serra,P, Howlett,S, Hunter,K, Garner,VE, Gonzalez-Munoz,A, Clark,J, Veijola,R, Cubbon,R, Chen,SL, Rosa,R, Cumiskey,AM, Serreze,DV, Gregory,S, Rogers,J, Lyons,PA, Healy,B, Smink,LJ, Todd,JA, Peterson,LB, Wicker,LS, Santamaria,P: Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. *Nat.Genet.* 39:329-337, 2007
  19. Diabetes Prevention Trial-Type 1 Diabetes Study Group: Effects of insulin in relative of patients with type 1 diabetes mellitus. *N Engl J Med* 346:1685-1691, 2002
  20. Atkinson,MA, Maclaren,NK, Luchetta,R: Insulinitis and diabetes in NOD mice reduced by prophylactic insulin therapy. *Diabetes* 39:933-937, 1990
  21. Bowman,MA, Campbell,L, Darrow,BL, Ellis,TM, Suresh,A, Atkinson,MA: Immunological and metabolic effects of prophylactic insulin therapy in the NOD-scid/scid adoptive transfer model of IDDM. *Diabetes* 45:205-208, 1996
  22. Keller,RJ, Eisenbarth,GS, Jackson,RA: Insulin prophylaxis in individuals at high risk of type I diabetes. *Lancet* 341:927-928, 1993
  23. Fuchtenbusch,M, Rabl,W, Grassl,B, Bachmann,W, Standl,E, Ziegler,AG: Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial. *Diabetologia* 41:536-541, 1998
  24. Skyler,JS, Krischer,JP, Wolfsdorf,J, Cowie,C, Palmer,JP, Greenbaum,C, Cuthbertson,D, Rafkin-Mervis,LE, Chase,HP, Leschek,E: Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. *Diabetes Care* 28:1068-1076, 2005
  25. Erlich,H, Valdes,AM, Noble,J, Carlson,JA, Varney,M, Concannon,P, Mychaleckyj,JC, Todd,JA, Bonella,P, Fear,AL, Lavant,E, Louey,A, Moonsamy,P: HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. *Diabetes* 57:1084-1092, 2008
  26. Julier,C, Hyer,RN, Davies,J, Merlin,F, Soularue,P, Briant,L, Cathelineau,G, Deschamps,I, otter,JI, Froguel,P, Boitard,C, Bell,JI, Lathrop,GM: Insulin-IGF2 region on chromosome 11p encodes a gene implicated in HLA-DR4-dependent diabetes susceptibility. *Nature* 354:155-159, 1991
  27. Knight,JC, Keating,BJ, Kwiatkowski,DP: Allele-specific repression of lymphotoxin-alpha by activated B cell factor-1. *Nat.Genet.* 36:394-399, 2004

28. Butty,V, Roy,M, Sabeti,P, Besse,W, Benoist,C, Mathis,D: Signatures of strong population differentiation shape extended haplotypes across the human CD28, CTLA4, and ICOS costimulatory genes. *Proc Natl.Acad Sci U S.A.* 104:570-575, 2007
29. Qu,HQ, Montpetit,A, Ge,B, Hudson,TJ, Polychronakos,C: Toward further mapping of the association between the IL2RA locus and type 1 diabetes. *Diabetes* 56:1174-1176, 2007
30. Smyth,DJ, Cooper,JD, Bailey,R, Field,S, Burren,O, Smink,LJ, Guja,C, Ionescu-Tirgoviste,c, Widmer,B, Dunger,DB, Savage,DA, Walker,NM, Clayton,DG, Todd,JA: A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. *Nat.Genet.* 38:617-619, 2006
31. Rodacki,M, Svoren,B, Butty,V, Besse,W, Laffel,L, Benoist,C, Mathis,D: Altered natural killer cells in type 1 diabetic patients. *Diabetes* 56:177-185, 2007
32. Lowe,CE, Cooper,JD, Brusko,T, Walker,NM, Smyth,DJ, Bailey,R, Bourget,K, Plagnol,V, Field,S, Atkinson,M, Clayton,DG, Wicker,LS, Todd,JA: Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. *Nat.Genet.* 39:1074-1082, 2007
33. Guja,C, Guja,L, Nutland,S, Rance,H, Sebastien,M, Todd,JA, Ionescu-Tirgoviste,c: Type 1 diabetes genetic susceptibility encoded by HLA DQB1 genes in Romania. *J Cell Mol Med* 8:249-256, 2004
34. Lie,BA, Ronningen,KS, Akselsen,HE, Thorsby,E, Undlien,DE: Application and interpretation of transmission/disequilibrium tests: transmission of HLA-DQ haplotypes to unaffected siblings in 526 families with type 1 diabetes. *Am J Hum.Genet.* 66:740-743, 2000
35. Kawasaki,E, Noble,J, Erlich,H, Mulgrew,CL, Fain,PR, Eisenbarth,GS: Transmission of DQ haplotypes to patients with type 1 diabetes. *Diabetes* 47:1971-1973, 1998
36. Stephens,M, Smith,NJ, Donnelly,P: A new statistical method for haplotype reconstruction from population data. *Am J Hum Genet* 68:978-989, 2001
37. Motohashi,Y, Yamada,S, Yanagawa,T, Maruyama,T, Suzuki,R, Niino,M, Fukazawa,T, Kasuga,A, Hirose,H, Matsubara,K, Shimada,A, Saruta,T: Vitamin D receptor gene polymorphism affects onset pattern of type 1 diabetes. *J Clin Endocrinol Metab* 88:3137-3140, 2003
38. Moore,AF, Florez,JC: Genetic susceptibility to type 2 diabetes and implications for antidiabetic therapy. *Annu Rev.Med* 59:95-111, 2008
39. Brophy,K, Ryan,AW, Thornton,JM, Abuzakouk,M, Fitzgerald,AP, McLoughlin,RM, O'morain,C, Kennedy,NP, Stevens,FM, Feighery,C, Kelleher,D, McManus,R: Haplotypes in the CTLA4 region are associated with coeliac disease in the Irish population. *Genes.Immun.* 7:19-26, 2006
40. Graham,J, Hagopian,WA, Kockum,I, Li,LS, Sanjeevi,CB, Lowe,RM, Schafer,JB, Zarghami,M, Day,HL, Landin-Olsson,M, Palmer,JP, Janer-Villanueva,M, Hood,L, Sundkvist,G, Lernmark,A, Breslow,N, Dahlquist,G, Blohme,G, Diabetes Incidence in Sweden Study Group, Swedish Childhood Diabetes Study Group: Genetics effects on age-dependent onset and islet cell autoantibody markers in type 1 diabetes. *Diabetes Care* 26:226-229, 2003
41. Hermann,R, Laine,AP, Veijola,R, Vahlberg,T, Simell,S, Lahde,J, Simell,O, Knip,M, Ilonen,J: The effect of HLA class II, insulin and CTLA4 gene regions on the development of humoral beta cell autoimmunity. *Diabetologia* 48:1766-1775, 2005

42. Nielsen, LB, Mortensen, HB, Chiarelli, F, Holl, R, Swift, P, de Beaufort, C, Pociot, F, Hougaard, P, Gammeltoft, S, Knip, M, Hansen, L: Impact of IDDM2 on disease pathogenesis and progression in children with newly diagnosed type 1 diabetes: reduced insulin antibody titres and preserved beta cell function. *Diabetologia* 49:71-74, 2006
43. Redondo, MJ, Babu, S, Zeidler, A, Orban, T, Yu, L, Greenbaum, C, Palmer, JP, Cuthbertson, D, Eisenbarth, GS, Krischer, JP, Schatz, D: Specific human leukocyte antigen DQ influence on expression of antiislet autoantibodies and progression to type 1 diabetes. *J Clin Endocrinol Metab* 91:1705-1713, 2006
44. Ziegler, AG, Standl, E, Albert, E, Mehnert, H: HLA-associated insulin autoantibody formation in newly diagnosed type I diabetic patients. *Diabetes* 40:1146-1149, 1991
45. Thomson, G, Valdes, AM, Noble, JA, Kockum, I, Grote, MN, Najman, J, Erlich, HA, Cucca, F, Pugliese, A, Steenkiste, A, Dorman, JS, Caillat-Zucman, S, Hermann, R, Ilonen, J, Lambert, AP, Bingley, PJ, Gillespie, KM, Lernmark, A, Sanjeevi, CB, Ronningen, KS, Undlien, DE, Thorsby, E, Petrone, A, Buzzetti, R, Koeleman, BP, Roep, BO, Saruhan-Direskeneli, G, Uyar, FA, Gunoz, H, Gorodezky, C, Alaez, C, Boehm, BO, Mlynarski, W, Ikegami, H, Berrino, M, Fasano, ME, Dametto, E, Israel, S, Brautbar, C, Santiago-Cortes, A, Frazer, dL, She, JX, Bugawan, TL, Rotter, JI, Raffel, L, Zeidler, A, Leyva-Cobian, F, Hawkins, BR, Chan, SH, Castano, L, Pociot, F, Nerup, J: Relative predispositional effects of HLA class II DRB1-DQB1 haplotypes and genotypes on type 1 diabetes: a meta-analysis. *Tissue Antigens*. 70:110-127, 2007
46. Hagopian, WA, Sanjeevi, CB, Kockum, I, Landin-Olsson, M, Karlsen, AE, Sundkvist, G, Dahlquist, G, Palmer, J, Lernmark, A: Glutamate decarboxylase-, insulin-, and islet cell-antibodies and HLA typing to detect diabetes in a general population-based study of Swedish children. *J Clin Invest* 95:1505-1511, 1995
47. Aly, TA, Ide, A, Jahromi, MM, Barker, JM, Fernando, MS, Babu, SR, Yu, L, Miao, D, Erlich, HA, Fain, PR, Barriga, KJ, Norris, JM, Rewers, MJ, Eisenbarth, GS: Extreme genetic risk for type 1A diabetes. *Proc Natl. Acad Sci U S A*. 103:14074-14079, 2006
48. Stratmann, T, Martin-Orozco, N, Mallet-Designe, V, McGavern, D, Losyev, G, Dobbs, C, Oldstone, MBA, Yoshida, K, Kikutani, H, Mathis, D, Benoist, C, Haskins, K, Teyton, L: Susceptible MHC alleles, not background genes, select an autoimmune T cell reactivity. *J. Clin. Invest.* 112:902-914, 2003
49. Nejentsev, S, Howson, JM, Walker, NM, Szeszko, J, Field, SF, Stevens, HE, Reynolds, P, Hardy, M, King, E, Masters, J, Hulme, J, Maier, LM, Smyth, D, Bailey, R, Cooper, JD, Ribas, G, Campbell, RD, Clayton, DG, Todd, JA, Burton, PR, Clayton, DG, Cardon, LR, Craddock, N, Deloukas, P, Duncanson, A, Kwiatkowski, DP, McCarthy, MI, Ouwehand, WH, Samani, NJ, Todd, JA, Donnelly, P, Barrett, JC, Burton, PR, Davison, D, Donnelly, P, Easton, D, Evans, D, Leung, HT, Marchini, JL, Morris, AP, Spencer, CC, Tobin, MD, Cardon, LR, Clayton, DG, Attwood, AP, Boorman, JP, Cant, B, Everson, U, Hussey, JM, Jolley, JD, Knight, AS, Koch, K, Meech, E, Nutland, S, Prowse, CV, Stevens, HE, Taylor, NC, Walters, GR, Walker, NM, Watkins, NA, Winzer, T, Todd, JA, Ouwehand, WH, Jones, RW, McArdle, WL, Ring, SM, Strachan, DP, Pembrey, M, Breen, G, St Clair, D, Caesar, S, Gordon-Smith, K, Jones, L, Fraser, C, Green, EK, Grozeva, D, Hamshere, ML, Holmans, PA, Jones, IR, Kirov, G, Moskvina, V, Nikolov, I, O'Donovan, MC, Owen, MJ, Craddock, N, Collier, DA, Elkin, A, Farmer, A, Williamson, R, McGuffin, P, Young, AH, Nicol, F, I, Ball, SG, Balmforth, AJ, Barrett, JH, Bishop, DT, Iles, MM, Maqbool, A, Yuldasheva, N, Hall, AS, Braund, PS, Burton, PR, Dixon, RJ, Mangino, M, Stevens, S, Tobin, MD, Thompson, JR, Samani, NJ,

- Bredin,F, Tremelling,M, Parkes,M, Drummond,H, Lees,CW, Nimmo,ER, Satsangi,J, Fisher,SA, Forbes,A, Lewis,CM, Onnie,CM, Prescott,NJ, Sanderson,J, Mathew,CG, Barbour,J, Khalid,MM, Todhunter,CE, Mansfield,JC, Ahmad,T, Cummings,FR, Jewell,DP, Webster,J, Brown,MJ, Clayton,DG, Lathrop,GM, Connell,J, Dominiczak,A, Samani,NJ, Braga,CA, Burke,B, Dobson,R, Gungadoo,J, Lee,KL, Munroe,PB, Newhouse,SJ, Onipinla,A, Wallace,C, Xue,M, Caulfield,M, Farrall,M, Barton,A, Bruce,IN, Donovan,H, Eyre,S, Gilbert,PD, Hider,SL, Hinks,AM, John,SL, Potter,C, Silman,AJ, Symmons,DP, Thomson,W, Worthington,J, Clayton,DG, Dunger,DB, Nutland,S, Stevens,HE, Walker,NM, Widmer,B, Todd,JA, Frayling,TM, Freathy,RM, Lango,H, Perry, JR, Shields,BM, Weedon,MN, Hattersley,AT, Hitman,GA, Walker,M, Elliott,KS, Groves,CJ, Lindgren,CM, Rayner,NW, Timpson,NJ, Zeggini,E, McCarthy,MI, Newport,M, Sirugo,G, Lyons,E, Vannberg,F, Hill,AV, Bradbury,LA, Farrar,C, Pointon,JJ, Wordsworth,P, Brown,MA, Franklyn,JA, Heward, JM, Simmonds,MJ, Gough,SC, Seal,S, Stratton,MR, Rahman,N, Ban,M, Goris,A, Sawcer,SJ, Compston,A, Conway,D, Jallow,M, Newport,M, Sirugo,G, Rockett,KA, Kwiatkowski,DP, Bryan,C, Bumpstead,SJ, Chaney,A, Downes,K, Ghori,J, Gwilliam,R, Hunt,SE, Inouye,M, Keniry,A, King,E, McGinnis,R, Potter,S, Ravindrarajah,R, Whittaker,P, Withers,D, Deloukas,P, Leung,HT, Nutland,S, Stevens,HE, Walker,NM, Todd,JA, Easton,D, Clayton,DG, Burton,PR, Tobin,MD, Barrett,JC, Evans,D, Morris,AP, Cardon,LR, Cardin,NJ, Davison,D, Ferreira,T, Pereira-Gale,J, Hallgrimsdottir,IB, Howie,BN, Marchini,JL, Spencer,CC, Su,Z, Ying,TY, Vukcevic,D, Donnelly,P, Bentley,D, Brown,MA, Cardon,LR: Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. *Nature*. 2007
50. Skyler,JS: Prediction and prevention of type 1 diabetes: progress, problems, and prospects. *Clin Pharmacol.Ther* 81:768-771, 2007

Chrom	GeneName	Polymorphism	Alleles		rs#	Allele counts 0/1/2		Min. allele freq.		OR	CI	p	lit.	<i>apMa</i>			
			0	1		Nprog	Prog	Nprog	Prog					CEU	DCGS	lit.	DCGS
6	Lymphotoxin- $\alpha$	+10	G	A	rs1800683	137 / 173 / 39	115 / 95 / 17	0.36	0.28	1.41	1.1 - 1.83	9.4E-03	0.36		0.34		0.44
11	Insulin	-23 HphI	T	A	rs689	16 / 109 / 221	7 / 63 / 153	0.20	0.17	1.23	0.9 - 1.67	0.22	0.32	0.24	0.28	0.12	0.18
1	PTPN22	R620W	C	T	rs2476601	253 / 86 / 9	155 / 66 / 6	0.15	0.17	1.18	0.86 - 1.63	0.35	0.06 - 0.15	0.14	0.08	0.15 - 0.17	0.19
10	IL-2 Ra (CD25)	Intron 1	G	A	rs706778	106 / 175 / 64	57 / 124 / 45	0.44	0.47	1.15	0.91 - 1.46	0.28	0.4 - 0.45	0.45	0.39*	0.45	0.48*
10	IL-2 Ra (CD25)	Intron 1	T	C	rs3118470	145 / 160 / 41	85 / 115 / 26	0.35	0.37	1.09	0.85 - 1.39	0.54	0.32 - 0.34	0.29	0.25*	0.36	0.38*
10	IL-2 Ra (CD25)	IL-2 Ra region	C	A	rs41295061	307 / 36 / 5	194 / 28 / 1	0.07	0.07	1.02	0.63 - 1.64	0.96	0.11			0.07	
10	IL-2 Ra (CD25)	IL-2 Ra region	T	A	rs11594656	204 / 119 / 20	141 / 67 / 13	0.23	0.21	1.13	0.85 - 1.51	0.44	0.25	0.21		0.22	
2	IFIH1	A946T	C	T	rs1990760	43 / 139 / 143	25 / 104 / 93	0.35	0.35	1.00	0.78 - 1.29	0.97	0.39	0.39		0.35	
1	Fc receptor-like 3	Prom -169	A	G	rs7528684	99 / 174 / 67	74 / 107 / 42	0.45	0.43	1.11	0.87 - 1.41	0.45	0.45	0.44	0.49		0.44
6	C6orf118	M256I	C	A	rs510579	144 / 158 / 42	88 / 111 / 25	0.35	0.36	1.03	0.81 - 1.33	0.84	0.35		0.36		0.38
5	CAPSL	R75Q	A	G	rs1445898	55 / 184 / 94	41 / 103 / 68	0.44	0.44	1.02	0.8 - 1.31	0.92	0.44	0.39		0.41	
2	CTLA-4	Prom -1577	G	A	rs11571316	129 / 176 / 42	90 / 102 / 32	0.37	0.37	1.02	0.8 - 1.3	0.94	0.42	0.47	0.46	0.35	0.42
2	CTLA-4	Prom -318	T	C	rs5742909	0 / 60 / 278	2 / 34 / 188	0.09	0.08	1.05	0.69 - 1.61	0.90	0.11	0.06	0.06	0.09	0.08
2	CTLA-4	T49A	G	A	rs231775	57 / 175 / 111	43 / 115 / 66	0.42	0.45	1.12	0.88 - 1.42	0.40	0.43	0.38	0.38	0.29	0.42
2	CTLA-4	3'UTR 6230 (CT60)	G	A	rs3087243	117 / 181 / 48	84 / 105 / 35	0.40	0.39	1.04	0.82 - 1.33	0.79	0.48	0.46	0.47	0.37	0.43
2	CTLA-4	JO31	C	A	rs11571302	101 / 176 / 47	74 / 108 / 38	0.42	0.42	1.01	0.79 - 1.29	0.99	0.50		0.49	0.39	0.47
2	CD28	Intron 1	C	T	rs10932017	74 / 182 / 90	43 / 116 / 64	0.48	0.45	1.10	0.87 - 1.4	0.47	0.44	0.42	0.43		0.45
2	CD28	Intron 1	A	T	rs2013278	39 / 145 / 148	25 / 98 / 97	0.34	0.34	1.00	0.78 - 1.29	0.96	0.36		0.23		0.26
2	CD28	3'UTR	G	T	rs3181113	313 / 35 / 0	211 / 11 / 1	0.05	0.03	1.76	0.92 - 3.37	0.11	0.03	0.03	0.04		0.02
2	CD28	3'UTR	T	A	rs11681201	22 / 117 / 210	12 / 87 / 128	0.23	0.24	1.08	0.82 - 1.42	0.64	0.13	0.20	0.15		0.18
2	ICOS	Prom -1817	T	C	rs4452124	263 / 76 / 5	182 / 38 / 2	0.13	0.09	1.37	0.93 - 2.02	0.14	0.08	0.06	0.08		0.07
2	ICOS	Intron 1	C	T	rs4335928	0 / 79 / 269	4 / 52 / 170	0.11	0.13	1.20	0.84 - 1.71	0.38	0.11	0.10	0.10	0.13	0.12
2	ICOS	Intron 1	C	T	rs4675377	20 / 146 / 179	13 / 92 / 121	0.27	0.26	1.04	0.8 - 1.37	0.80	0.17	0.18	0.22		0.26
12	VDR	BsmI Intron3	T	C	rs1544410	142 / 146 / 56	86 / 99 / 38	0.38	0.39	1.08	0.84 - 1.37	0.60	0.12 - 0.25	0.44	0.38	0.12 - 0.23	0.38
4	TLR2	S450S	T	C	rs3804100	302 / 38 / 1	197 / 25 / 2	0.06	0.06	1.11	0.68 - 1.82	0.77	0.41†	0.05	0.07	0.39†	0.07
19	KIR 2DS3		AbsPres			252 / 80 / 0	158 / 60 / 0	0.12	0.14	1.16	0.81 - 1.67	0.46	0.38		0.32	0.21	0.41
10	TCF7L2	Intron 3	C	T	rs7903146	182 / 134 / 31	115 / 90 / 21	0.28	0.29	1.05	0.81 - 1.36	0.78	0.29	0.25	0.31	0.41	0.30
8	SLC30A8	R325W	C	T	rs13266634	187 / 131 / 30	116 / 86 / 24	0.27	0.30	1.11	0.86 - 1.45	0.46	0.30	0.25	0.29	0.25	0.31
10	HHEX	HHEX region	A	G	rs7923837	48 / 160 / 136	33 / 112 / 81	0.37	0.39	1.10	0.86 - 1.4	0.50	0.38	0.38	0.37	0.34	0.40
10	HHEX	HHEX region	G	A	rs1111875	115 / 179 / 54	73 / 108 / 45	0.41	0.44	1.11	0.87 - 1.41	0.42	0.40	0.44	0.39	0.36	0.41
11	LOC387761	Intron 5	G	A	rs7480010	189 / 139 / 21	115 / 92 / 19	0.26	0.29	1.15	0.88 - 1.5	0.32	0.30	0.25	0.30	0.34	0.32
11	EXT2	Intron 14	A	G	rs3740878	200 / 124 / 21	119 / 96 / 11	0.24	0.26	1.12	0.85 - 1.47	0.48	0.27	0.30	0.27	0.24	0.27
12	ERBB2	Intron 7	A	C	rs2292239	46 / 191 / 109	35 / 100 / 190	0.41	0.38	1.14	0.89 - 1.45	0.32	0.36	0.30		0.41	
18	PTPN2	Intron 7	T	C	rs1893217	236 / 101 / 8	149 / 62 / 14	0.17	0.20	1.22	0.9 - 1.66	0.22	0.17	0.19		0.21	
12	SH2B3	Exon 3	C	T	rs3184504	85 / 168 / 89	54 / 111 / 58	0.49	0.49	1.01	0.8 - 1.29	0.97	0.49	0.41		0.56	
12	C12Orf30	Intron 15	A	G	rs17696736	99 / 174 / 72	72 / 105 / 47	0.46	0.44	1.07	0.84 - 1.36	0.62	0.43	0.35		0.49	
16	CLEC16A	Intron 19	A	G	rs12708716	160 / 147 / 33	100 / 90 / 30	0.31	0.34	1.13	0.88 - 1.46	0.37	0.35	0.29		0.31	

\* Allele frequencies from the DAVY study (ref 34). † Allele frequency in Koreans

*Genetic determinants of Type 1 DM progression*

**Table 2 : HLA DQbeta alleles and progression to diabetes****2A**

DQβ Alleles	N P	N NP	% in P	% in NP	Parental freqs.		p-val <sup>†</sup>	OR (95% CI) <sup>†</sup>	Median (y) <sup>‡</sup>
					T1DGC	DPT1			
0201	158	245	31.7%	31.5%	23.2%	22.1%	0.93	1.01 (0.79 - 1.29)	12.3
0301	43	111	8.6%	14.3%	13%	13.7%	2.59E-03	0.57 (0.39 - 0.82)	11.9
0302	212	270	42.6%	34.7%	32.8%	28.7%	4.70E-03	1.39 (1.11 - 1.76)	12.6
0303	4	9	0.8%	1.2%	3.5%	1.4%	0.54	0.69 (0.21 - 2.26)	13.1
0402	11	15	2.2%	1.9%	1.9%	2.4%	0.73	1.15 (0.52 - 2.52)	11.2
0501	33	54	6.6%	6.9%	7.1%	7.3%	0.83	0.95 (0.61 - 1.49)	13.1
0502	5	10	1.0%	1.3%	1.1%	-	0.65	0.78 (0.26 - 2.29)	6.7
0603	11	19	2.2%	2.4%	3.1%	6.5%	0.79	0.9 (0.43 - 1.91)	12.0
0604	16	27	3.2%	3.5%	4.7%	2.6%	0.80	0.92 (0.49 - 1.73)	16.6

**2B****Among 0302, 0301 or 0201+ Individuals**

DQβ Alleles	N P	N NP	% in P	% in NP	p-val <sup>†</sup>	OR (95% CI) <sup>†</sup>	Median (y) <sup>‡</sup>	Survival pval
0302/ 0201	87	121	48.1%	50.6%	0.60	0.9 (0.61 - 1.33)	12.07	0.27
0302/ 0301	21	30	11.6%	12.6%	0.77	0.91 (0.5 - 1.66)	11.77	0.93
0302/ 0302	31	31	17.1%	13.0%	0.72	1.39 (0.81 - 2.38)	13.05	0.05
0302/ 0402	6	5	3.3%	2.1%	0.44	1.6 (0.48 - 5.34)	11.04	0.38
0302/ 0501	18	17	9.9%	7.1%	0.30	1.44 (0.72 - 2.88)	12.89	0.72
0302/ 0603	6	11	3.3%	4.6%	0.51	0.71 (0.26 - 1.96)	11.85	0.74
0302/ 0604	5	11	2.8%	4.6%	0.33	0.59 (0.2 - 1.73)	16.36	0.55
0301/ 0201	5	36	12.5%	35.6%	6.4E-03	0.26 (0.09 - 0.72)	14.16	5.5E-03
0301/ 0301	3	10	7.5%	9.9%	0.65	0.73 (0.19 - 2.84)	11.57	0.58
0301/ 0501	4	11	10.0%	10.9%	0.88	0.91 (0.27 - 3.04)	10.72	0.69
0301/ 0604	5	6	12.5%	5.9%	0.19	2.26 (0.65 - 7.88)	11.36	0.41
0301/ 0302	21	30	52.5%	29.7%	0.01	2.62 (1.23 - 5.56)	11.77	2.8E-03
0201/ 0201	20	25	14.6%	11.4%	0.38	1.33 (0.71 - 2.51)	11.23	0.13
0201/ 0301	5	36	3.6%	16.4%	2.5E-04	0.19 (0.07 - 0.51)	14.16	2.3E-04
0201/ 0302	87	121	63.5%	55.0%	0.11	1.42 (0.92 - 2.21)	12.07	0.29
0201/ 0402	4	7	2.9%	3.2%	0.89	0.92 (0.26 - 3.19)	13.71	0.74
0201/ 0501	8	6	5.8%	2.7%	0.14	2.21 (0.75 - 6.52)	10.38	0.17
0201/ 0603	4	3	2.9%	1.4%	0.30	2.18 (0.48 - 9.87)	12.71	0.50
0201/ 0604	4	8	2.9%	3.6%	0.71	0.8 (0.24 - 2.7)	14.09	0.95

† for P vs. NP comparisons

\* for P vs. NP comparisons within a given HLA-DQB+ group

‡ age of onset in P

**Table 3: initial IAA titers and T1D susceptibility loci genotypes**

Gene	Polymorphism	Allele 0 Allele 1		Median IAA level by genotype					Linear regression p-values		
				0	1	2	0&1	1&2	0-1-2	0 vs. 1&2	0&1 vs. 2
HLA-DQB1	DQB1*0302	Counts		115	183	156	150	180.2	0.034	0.67	1.36E-02
HLA-DQB1	DQB*0201	Counts		176	164	82	169	135	0.044	0.40	1.80E-03
	*0302/0201	Abs	Pres	137.5	210				0.013		
HLA-DQB1	DQB*0301	Counts		168	124	82.5	153	124	0.16	0.714	0.14
Lymphotoxin- $\alpha$	+10	G	A	153	150	144	150	150	0.75	0.62	0.91
Insulin	-23 HphI	T	A	61	111	192	104	164.5	3.74E-05	1.05E-04	0.014
PTPN22	R620W	C	T	145	177	220	150	178	0.37	0.56	0.42
IL-2 Ra (CD25)	Intron 1	G	A	166	173	103	168	149.5	0.46	0.11	0.80
IL-2 Ra (CD25)	Intron 1	T	C	161.5	166	120	165	150	0.76	0.30	0.78
IL-2 Ra (CD25)	CD25 region	C	A	148	162.5	87	150	156	0.35	0.88	0.45
IL-2 Ra (CD25)	CD25 region	T	A	146	166.5	98	150	165	0.65	0.43	0.66
IFIH1	A946T	C	T	124	154.5	149	147	150	0.35	0.56	0.29
Fc receptor-like 3	Prom -169	A	G	177.5	141.5	142	151.5	142	0.55	0.94	0.39
C6orf118	M256I	C	A	153	153	121.5	153	150	0.62	0.63	0.73
CAPSL	R75Q	A	G	131.5	164	141	150	157.5	0.74	0.71	0.31
CTLA-4	Prom -1577	G	A	183	135	139.5	156	136	0.044	0.21	0.06
CTLA-4	Prom -318	T	C	18	152.5	150	147	150	0.53	0.33	0.08
CTLA-4	T49A	G	A	148.5	146.5	147	148	147	0.73	0.95	0.49
CTLA-4	3'UTR 6230 (CT60)	G	A	187.5	135	139.5	156	136	0.037	0.22	0.041
CTLA-4	JO31	C	A	174	146	148	162	146	0.16	0.26	0.24
CD28	Intron 1	C	T	131	165.5	141.5	153	159.5	0.63	0.57	0.15
CD28	Intron 1	A	T	171	147	147	150	147	0.41	0.56	0.40
CD28	3'UTR	G	T	157.5	132	540	150	133.5	0.15	0.38	0.11
CD28	3'UTR	T	A	194	159	141	168	149	0.051	0.07	0.22
ICOS	Prom -1817	T	C	148	160	203	150	166.5	0.09	0.26	0.13
ICOS	Intron 1	C	T	63	182.5	141.5	179	153	0.17	0.11	0.42
ICOS	Intron 1	C	T	382.5	168	135.5	178.5	144.5	4.08E-03	0.044	1.54E-03
VDR	BsmI Intron3	T	C	153	131	116	150	128	0.87	0.62	0.78
TLR2	S450S	T	C	150	142	NA	150	142	0.59		
KIR 2DS3		Abs	Pres	142	150	212	146	164.5	0.66	0.37	0.94
TCF7L2	Intron 3	C	T	138	166.5	225.5	149	173.5	0.26	0.24	0.43
SLC30A8	R325W	C	T	177	147	162.5	147	150	0.63	0.55	0.91
HHEX	HHEX region	A	G	170.5	142	174	149	147	0.98	0.76	0.84
HHEX	HHEX region	G	A	145	181.5	92	156	168	0.97	0.08	0.40
LOC387761	Intron 5	G	A	169	131	180	150	133	0.85	0.27	0.76
EXT2	Intron 14	A	G	218	231.5	182	218	188	0.17	0.22	0.17
ERBB2	Intron 7	A	C	210	120	177	137	141	0.72	0.14	0.19
PTPN2	Intron 7	T	C	148	177	126	156	170	0.84	0.80	0.73
SH2B3	Exon 3	C	T	169	156	134	160	144.5	0.70	0.86	0.40
C12Orf30	Intron 15	A	G	141	177	124	162	157.5	0.52	0.69	0.17
CLEC16A	Intron 19	A	G	142	159	147.5	149.5	156	0.83	0.92	0.72

**Figure 1**

*CTLA4* haplotype representation in DPT1 individuals. **A)** Allelic composition of major *CTLA4* haplotypes computationally reconstructed in DPT1 individuals. For reference, corresponding frequencies in various population groups are indicated (CEPH-HGDP DNA panel (28)). **B)** Skewing (Odds ratio) of *CTLA4* SNPs/ haplotype frequency in DPT1 individuals when compared to ethnicity-matched control cohorts. **C)** Frequencies of major *CTLA4* haplotypes in DPT1 and control cohorts.


**A**

Haplotype #	CTLA4 SNPs					Freq. In Population groups				
	-1577	-318	+49	CT60	JO31	Africa	Middle-East	South Asia	East Asia	Caucasian
1	C	C	G	G	G	38%	25%	29%	62%	31%
2	T	C	A	A	T	10%	49%	58%	23%	49%
3	C	T	A	G	G	0%	8%	6%	12%	8%
4	C	C	A	G	G	30%	8%	4%	0%	4%
5	C	C	A	A	T	0%	3%	3%	0%	4%
6	C	C	G	G	T	0%	3%	0%	3%	0%
7	C	C	A	G	T	12%	2%	1%	0%	3%

**B**


	OR 95 CI of DPT1 vs.	
	DCGS	CEPH
-1577 T/C	0.74 (0.57 - 0.97)	0.64 (0.48 - 0.84)
-318 T/C	0.69 (0.41 - 1.16)	0.96 (0.59 - 1.59)
+49 A/G	0.72 (0.56 - 0.95)	0.55 (0.41 - 0.74)
CT60 A/G	0.78 (0.59 - 1.01)	0.6 (0.45 - 0.79)
JO31 T/G	0.77 (0.59 - 1)	0.58 (0.44 - 0.77)
CTLA4.h1/all others	1.56 (1.22 - 2)	2.36 (1.84 - 3.02)
CTLA4.h2/all others	0.69 (0.55 - 0.87)	0.75 (0.6 - 0.94)
CTLA4.h1/h2	2.26	3.15

**C**




**Figure 2**

Diabetes-free survival and HLA-DQB1 genotypes. Diabetes-free survival in **A)** all (n=638) or **B)** high-risk (n=295) individuals screened at age <10000 days according to their HLA-DQB1\*0302 or HLA-DQB1\*0301 genotypes. Significance of differences in survival is evaluated by log-rank test. The number of diabetes-free individuals in each category and at distinct time point is shown on the bottom of the figure. **C)** Disease-free survival in individuals screened at age <5000 or between 5000 and 10000 days, stratified based on their HLA-DQB1\*0302 or \*0301 genotypes.



**Figure 3**

Response to treatment according to HLA-DQB1 and *INS-23* genotype. **A)** All 638 individuals were stratified according to the number of HLA-DQB1\*0302 alleles, and treatment group. Significance of differences in survival is evaluated by log-rank test. I: intervention group P: placebo/ observation **B)** Individuals were stratified based on the number of *INS-23A* risk allele.



**Figure 4**

**A)** Cox proportional hazard modeling was applied to evaluate the individual contributions of DQB1 status and initial IAA levels to progression towards T1D. **B)** Diabete-free survival according to DQB1\*0302 status fitted on averaged IAA levels in the Cox model.

**A**

Variable	Coef.	exp(Coef)	SE	z	p
<b>Univariate</b>					
Initial IAA	0.16	1.18	0.05	3.28	1.00E-03
# 0302 alleles	0.39	1.47	0.11	3.67	2.40E-04
# 0301 alleles	-0.44	0.65	0.16	-2.75	5.90E-03
<b>Multivariate</b>					
IAA	0.16	1.17	0.05	3.16	1.60E-03
# 0302 alleles	0.38	1.46	0.11	3.55	3.80E-04
<b>Multivariate</b>					
IAA	0.15	1.17	0.05	3.11	1.90E-03
# 0301 alleles	-0.41	0.67	0.16	-2.57	1.00E-02

**B**

